NCT06839456RecruitingPhase 1/2
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT
Phase 1/2 Study: CD45RA Depleted Peripheral Stem Cell Addback to Prevent Viral and Fungal Infections Following Alternative Donor TCRab/CD19 Depleted Hematopoietic Stem Cell Transplant
Source: ClinicalTrials.gov · Last updated 15 Apr 2026
Brief summary (registry, in English)
The major morbidities of allogeneic hematopoietic stem cell transplant (HSCT) using donors that are not human leukocyte antigen (HLA) matched siblings are graft vs host disease (GVHD) and life- threatening infections. T cell receptor alpha beta (TCRαβ) T lymphocyte depletion and CD19+ B lymphocyte depletion of alternative donor hematopoietic stem cell (HSC) grafts is effective in preventing GVHD, but immune reconstitution may be delayed, increasing the risk of infections. The central hypothesis of this study is that an addback of CD45RO memory T lymphocytes, derived from a fraction of the original donor peripheral stem cell product depleted of CD45RA naïve T lymphocytes, will accelerate immune reconstitution and help decrease the risk of infections in TCRab/CD19 depleted PSCT.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 16 Feb 2025
- Start date
- 21 Mar 2025
- Primary completion date
- Mar 2031
- Lead sponsor
- Children's Hospital of Philadelphia
- Diseases
- Acute lymphoblastic leukaemia, Myelodysplastic syndromes, Acute myeloid leukemia, Childhood cancers
- NCT number
- NCT06839456
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 100
- From 21 Mar 2025 to the primary completion date, Mar 2031
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- HLA testing/matching
- HLA testing to be done by molecular methods for A, B, C, DRB1, DQB1
- Related donor: Must be ≥ 5/10 match
- Unrelated donor: 10/10 or 9/10 match
- KIR typing for haploidentical donor for hematologic malignancies
- Donor specific HLA antibodies (DSA) should be assessed for all subjects receiving an HLA mismatched graft (≤ 9/10).
Other illness
- Patients who do not meet institutional disease, organ or infectious criteria.
- Donor selection and eligibility:
Other
- Patients who have performance score less than 60.
- No suitable donor available for mobilized peripheral stem cells.
- Patients with Hodgkin lymphoma or non-Burkitt, non-lymphoblastic lymphoma.
- Planned receipt of alemtuzumab during conditioning.
- Patients with an available 10/10 HLA matched sibling donor.
- Unrelated donor meets National Marrow Donor Program criteria for donation.
- Related donor (at least haploidentical) willing and able to donate mobilized peripheral stem cells.
- Donor must be willing to undergo granulocyte colony stimulating factor (GCSF) mobilization and peripheral blood stem cell collection
- Donors must be willing to sign consent to participate in this study.
Who the study is looking for
- Disease for which allogeneic HSCT may be curative.
- Remission status of hematologic malignancies and additional disease-specific eligibility determinations will be according to standards of practice within the CHOP Cellular Immunotherapy and Transplant Program (CTTS).
- Patients must be 25 years of age and less
- Evaluation for organ and infectious status as per our CTTS standard operating procedure.
- Signed consent by parent/guardian or able to give consent if 18 years of age and older.
- Participants of childbearing potential must have a negative pregnancy test as per institutional SOP.
Age in the registry: 1 month to 25 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital of Philadelphia Coordinator of this site? Confirm its status | Philadelphia | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.